NCT00191906

Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD)

A Randomized, Double-Blind, Crossover Comparison of Atomoxetine and Placebo in Child Outpatients With Attention-Deficit/Hyperactivity Disorder, Reading Disorder, or Comorbid Attention-Deficit/Hyperactivity Disorder and Reading Disorder.

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 121 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 8 Years – 12 Years
• Healthy volunteers: Accepted

Summary

To test the hypothesis that a 4 week treatment with atomoxetine is more effective than placebo in patients with combined type Attention Deficit/Hyperactivity Disorder (ADHD), patients with only Reading Disorder, and patients with combined type ADHD and Reading Disorder.

Conditions

• Attention Deficit Hyperactivity Disorder
• Reading Disorder

Interventions

Type	Name	Description
DRUG	Atomoxetine Hydrochloride	Atomoxetine, 1.2 mg/kg/day, by mouth (PO)
DRUG	placebo	Placebo, every day (QD), by mouth (PO)

Timeline

• Start date: 2005-04-01
• Primary completion: 2007-12-01
• Completion: 2007-12-01
• First posted: 2005-09-19
• Last updated: 2010-05-25
• Results posted: 2010-04-06

Locations

5 sites across 2 countries: Belgium, Netherlands